Current efficacy of lysostaphin against Staphylococcus aureus strains relevant for burned patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F22%3AN0000260" target="_blank" >RIV/00027162:_____/22:N0000260 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Current efficacy of lysostaphin against Staphylococcus aureus strains relevant for burned patients

Popis výsledku v původním jazyce

Infectious complications play important role in morbidity and mortality in patients with burns. One of the most promising options, how we can manage the increasing resistance of pathogens, is the application of antibacterial enzymes called “enzybiotics”. The activity of lysostaphin was determined by the plate lysis assay and the turbidity assay. In the plate lysis assay, the bacterial suspension (108 CFU/mL) was plated on the blood agar, left to dry for 10 minutes and then lysostaphin was applied. In the turbidity assay, 10 µL of lysostaphin was added to 90 µL of the bacterial suspension (2 x 108 CFU/mL) in TSB in the microtiter plate. Then the turbidity of the culture medium was measured every 5 minutes during the 24-hour cultivation period to obtain bacterial growth curves. The plate lysis assay showed no bacterial growth even with the lowest concentration of lysostaphin tested (25 µg/mL) when freshly prepared lysostaphin was used. The antibacterial activity of lysostaphin stored for 12 weeks was lower, but still significantly reduced bacterial growth.

Název v anglickém jazyce

Current efficacy of lysostaphin against Staphylococcus aureus strains relevant for burned patients

Popis výsledku anglicky

Infectious complications play important role in morbidity and mortality in patients with burns. One of the most promising options, how we can manage the increasing resistance of pathogens, is the application of antibacterial enzymes called “enzybiotics”. The activity of lysostaphin was determined by the plate lysis assay and the turbidity assay. In the plate lysis assay, the bacterial suspension (108 CFU/mL) was plated on the blood agar, left to dry for 10 minutes and then lysostaphin was applied. In the turbidity assay, 10 µL of lysostaphin was added to 90 µL of the bacterial suspension (2 x 108 CFU/mL) in TSB in the microtiter plate. Then the turbidity of the culture medium was measured every 5 minutes during the 24-hour cultivation period to obtain bacterial growth curves. The plate lysis assay showed no bacterial growth even with the lowest concentration of lysostaphin tested (25 µg/mL) when freshly prepared lysostaphin was used. The antibacterial activity of lysostaphin stored for 12 weeks was lower, but still significantly reduced bacterial growth.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30303 - Infectious Diseases

Projekt

<a href="/cs/project/NV19-05-00214" target="_blank" >NV19-05-00214: Studium terapeutické aplikace antibakteriálního krytí rány pro infekce kůže a měkkých tkání u epidemiologicky relevantních kmenů S. aureus - rezistentních na meticilin.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů